



## Department of Health

**ANDREW M. CUOMO**  
Governor

**HOWARD A. ZUCKER, M.D., J.D.**  
Commissioner

**SALLY DRESLIN, M.S., R.N.**  
Executive Deputy Commissioner

September 21, 2018

Dear Health Care Provider,

The New York Newborn Screening Program (NBSP) is pleased to announce that we began screening for three new conditions on October 1, 2018: spinal muscular atrophy (SMA), mucopolysaccharidosis, type I (MPSI) and guanidinoacetate methyltransferase deficiency (GAMT). SMA and MPSI are part of the Secretary of Health and Human Services' Recommended Uniform Screening Panel (RUSP). With this addition, NYS will be screening for all the conditions on the RUSP.

This will have no effect on the collection and transport of the initial specimen to the Wadsworth Center. Likewise, there will be no changes in the other aspects of the program's screening for the 47 current conditions.

An information sheet about each condition is enclosed. Please note that newborns with an abnormal screen for MPSI and GAMT will be referred to one of the current Inherited Metabolic Specialty Care Centers for a diagnostic evaluation. Newborns with a positive screen for SMA will be referred to the newly designated Neuromuscular Specialty Care Centers. Follow-up staff from the NBSP will direct these referrals and advise each of you of actions needed on your part.

Questions about these new conditions can be directed to our main telephone number: (518) 473-7552. Thank you for your continued support of the NYS Newborn Screening Program.

Sincerely,

Michele Caggana, Sc.D., FACMG  
Director, Newborn Screening Program  
Wadsworth Center  
New York State Department of Health